Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $371.1 million.

  • Xeris Biopharma Holdings' Total Liabilities rose 618.87% to $371.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $371.1 million, marking a year-over-year increase of 618.87%. This contributed to the annual value of $352.7 million for FY2024, which is 707.11% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Total Liabilities of $371.1 million as of Q3 2025, which was up 618.87% from $354.0 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Total Liabilities registered a high of $371.1 million during Q3 2025, and its lowest value of $133.7 million during Q3 2021.
  • For the 5-year period, Xeris Biopharma Holdings' Total Liabilities averaged around $300.6 million, with its median value being $323.9 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 103276.37% in 2021, then soared by 84.64% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Total Liabilities (Quarter) stood at $209.1 million in 2021, then skyrocketed by 43.13% to $299.3 million in 2022, then increased by 10.04% to $329.4 million in 2023, then increased by 7.07% to $352.7 million in 2024, then grew by 5.21% to $371.1 million in 2025.
  • Its Total Liabilities stands at $371.1 million for Q3 2025, versus $354.0 million for Q2 2025 and $350.6 million for Q1 2025.